ArticleBotanical studies2025
Anti-ageing and attenuating cognitive declines of Dicliptera chinensis extracts and purified compounds in vitro and in scopolamine-induced cognitive dysfunction mice.
Article in Botanical studies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe cognitive decline is one of the age-associated physical dysfunctions and also found in Alzheimer's disease (AD). The whole plants of Dicliptera chinensis (L.) Nees (DC) are belonged to edible materials as fresh vegetables, and dried DC powders as tea materials or used as folk medicines for clearing heat and removing toxic substance in Taiwan. However, DC extracts and the active compounds on anti-ageing and attenuating cognitive declines are not clear.
resultsThe dried powders of the whole DC plants are extracted with 95% ethanol to get DC-95EE. The DC-95EE is partitioned in sequences to get ethyl acetate fraction, butanol fraction (BuOH fraction), and water faction. Two flavone C-glycosides (vicenin II and schaftoside) are purified from the BuOH fraction. It is found that the pre-treatments of DC-95EE, BuOH fraction, and vicenin II and schaftoside show to elevate cell viabilities, reduce the senescence-associated β-galactosidase (SAβG) activity and intracellular reactive oxygen species (ROS) levels in galactose-treated SH-SY5Y neuronal cell models. The pre-treatments of vicenin II or schaftoside also show to lower ageing-associated p16 and p21 gene expressions and enhance SIRT-1 gene expressions in galactose-treated SH-SY5Y cells. The DC-95EE, vicenin II, and schaftoside show dose-dependent anti-acetylcholinesterase activities. The oral administrations of DC-95EE (200 mg/kg) and purified schaftoside (25 and 50 mg/kg) daily for 7 days ameliorate cognitive declines in scopolamine-induced ICR mice evaluated by Morris water maze. The quantification of vicenin II and schaftoside, respectively, account for 2.53% and 8.17% of DC-95EE by HPLC quantifications, which may be active compounds in the DC-95EE for anti-ageing activities.
conclusionThe DC-95EE exhibit anti-ageing in neuron cell models and attenuate cognitive declines in mice models, which may be potentials in developing functional foods for anti-ageing purposes and need further investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.